Post A Reply

Rate Stryker

  • Culture

  • Compensation

  • Opportunity for advancement

  • Realistic plan attainment

×

Salaries

In our drive to help people in the medical sales industry we are gathering salary data. This information will be collated, analyzed and number crunched. Medtechy’s overall goal is to help the medical sales industry make more informed decisions when changing jobs and also keep employers and recruiters honest

Take 30 seconds and let us know your current deal.*

About The Position

Compensation

* We guarantee all data collected is completely anonymous and will only be used for the benefit of future visitors.

×

Hot Ticker Articles

Diversified growth lifts Boston Scientific in Q1

Mazor Robotics Q1 2018 Investor Presentation

Intuitive Surgical hits 2018 priorities. Blows past Q1 expectations

Johnson & Johnson medical device business delivers 7.5% growth in Q1

Boston Scientific marketing gets innovative with new video series

Job Listings

When will Stryker make an SCS Acquisition

It's no secret Stryker has been looking to get into the SCS market. When will they finally pull the trigger and get in? Or will they develop their own?

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Stryker more likely to buy non-stim pain solutions. Big existing spine and interventional sales forces, no existing implanted stim infrastructure to leverage.

NeuroTech and Spine is the smallest business unit within Stryker so growing through one of the fastest growing medical device segments only makes sense. Pain/SCS makes a lot of sense.

post

Stryker more likely to buy non-stim pain solutions. Big existing spine and interventional sales forces, no existing implanted stim infrastructure to leverage.

Nuvectra would be a hit under Stryker ownership.

post

Stryker more likely to buy non-stim pain solutions. Big existing spine and interventional sales forces, no existing implanted stim infrastructure to leverage.

post

correct. Saluda will go to mdt if they go anywhere. Stryker will go with Nuvectra

You are correct unless some of the big boys are indirectly invested through the two venture capital funds that invested in the funding rounds. Those two are Action Potential Venture Capital and BioScience Managers Limited.

post

Isn't MDT pretty heavily invested into Saluda. Wouldn't they get first right or refusal?

correct. Saluda will go to mdt if they go anywhere. Stryker will go with Nuvectra

post

Saluda is practically a done deal. Plain and simple, it actually does what they claim it will do.

Isn't MDT pretty heavily invested into Saluda. Wouldn't they get first right or refusal?

post

Saluda is practically a done deal. Plain and simple, it actually does what they claim it will do.

Practically a done deal, huh....

post

count on it being SALUDA!!

Saluda is practically a done deal. Plain and simple, it actually does what they claim it will do.

post

Nuvectra is not a bad choice. Although the technology is "me too" it's still a viable product that from all accounts has produced pretty good outcomes. From a Stimwave standpoint, nobody is really sure what to think of this. A lot of rumors swirling in the wind about this company and not many positive rumors. Saluda may take too long to commercialize. So Nuvectra seems like the logical choice of the three...IM

Nope. Saluda is next. Stryker is on a spending spree and it isn't going to stop.

post

I seriously can't figure out if you all are being serious???

If Stryker is in fact going to jump in the SCS game and not develop their own product and salesforce, then they are going to acquire a company that has an FDA approved product with revenue. I guess Stimwave meets that criteria (kind of) but Stryker would probably steer clear based on all of the reasons listed in this thread.

Nevro would be too pricey and Nuvectra is good enough technology for Stryker to put their name on it.

So, why not Nuvectra?

Nuvectra is not a bad choice. Although the technology is "me too" it's still a viable product that from all accounts has produced pretty good outcomes. From a Stimwave standpoint, nobody is really sure what to think of this. A lot of rumors swirling in the wind about this company and not many positive rumors. Saluda may take too long to commercialize. So Nuvectra seems like the logical choice of the three...IM

post

count on it being SALUDA!!

I seriously can't figure out if you all are being serious???

If Stryker is in fact going to jump in the SCS game and not develop their own product and salesforce, then they are going to acquire a company that has an FDA approved product with revenue. I guess Stimwave meets that criteria (kind of) but Stryker would probably steer clear based on all of the reasons listed in this thread.

Nevro would be too pricey and Nuvectra is good enough technology for Stryker to put their name on it.

So, why not Nuvectra?

post

I hear Stimwave could be the target.

count on it being SALUDA!!

post

How long have you had bad hearing?

Count on saluda as Stryker's choice.

post

I hear Stimwave could be the target.

How long have you had bad hearing?

post

I could see Stryker holding out and making a play on a company like Saluda or Neuros whenever they establish themselves in the space. No reputable company will ever pick up st

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.